Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
GlaxoSmithKline Biologicals S.A.
J07BB02
pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Vaccines
Influenza, Human; Immunization; Disease Outbreaks
Prophylaxis of influenza in an officially declared pandemic situation.Pandemic-influenza vaccine should be used in accordance with official guidance.
Revision: 4
Withdrawn
2011-03-04
31 B. PACKAGE LEAFLET Medicinal product no longer authorised 32 PACKAGE LEAFLET: INFORMATION FOR THE USER PUMARIX SUSPENSION AND EMULSION FOR EMULSION FOR INJECTION Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU RECEIVE THIS VACCINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or nurse. - This vaccine has been prescribed for you only. Do not pass it on to others. - If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET : 1. What Pumarix is and what it is used for 2. What you need to know before you are given Pumarix 3. How Pumarix is given 4. Possible side effects 5. How to store Pumarix 6. Contents of the pack and other information 1. WHAT PUMARIX IS AND WHAT IT IS USED FOR WHAT PUMARIX IS AND WHAT IT IS USED FOR Pumarix is a vaccine for use in adults from 18 years old to prevent pandemic flu (influenza). Pandemic flu is a type of influenza that happens at intervals that vary from less than 10 years to many decades. It spreads rapidly around the world. The signs of pandemic flu are similar to those of ordinary flu but may be more serious. HOW PUMARIX WORKS When a person is given the vaccine, the body’s natural defence system (immune system) produces its own protection (antibodies) against the disease. None of the ingredients in the vaccine can cause flu. As with all vaccines, Pumarix may not fully protect all persons who are vaccinated. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN PUMARIX PUMARIX SHOULD NOT BE GIVEN: • if you have previously had a sudden life-threatening allergic reaction to any ingredient of this vaccine (listed in section 6) or to anything else that may be present in very small amounts, such as: egg and chicken protein, ovalbumin, formaldehyde or sodium deoxycholate. - Signs of an allergic reaction may include itchy skin r Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Pumarix suspension and emulsion for emulsion for injection Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen * equivalent to: _ _ A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms ** * propagated in eggs ** haemagglutinin This vaccine complies with the WHO recommendation and EU decision for the pandemic. AS03 adjuvant composed of squalene (10.69 milligrams), DL- α -tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams) The suspension and emulsion, once mixed, form a multidose vaccine in a vial. See section 6.5 for the number of doses per vial. Excipient with known effect: the vaccine contains 5 micrograms thiomersal For the full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Suspension and emulsion for emulsion for injection. The suspension is a translucent to off white opalescent suspension, which may sediment slightly. The emulsion is a whitish homogeneous liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza in an officially declared pandemic situation (see sections 4.2 and 5.1). Pandemic influenza vaccine should be used in accordance with official guidance. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults from the age of 18 years onwards: _ One dose of 0.5 ml at an elected date. A second dose of 0.5 ml should be given after an interval of at least three weeks. Medicinal product no longer authorised 3 _Persons previously vaccinated with one or two doses of AS03-containing vaccine containing HA _ _derived from a different clade of the same subtype _ Adults from the age of 18 years onwards: one dose of 0.5 ml at an elected date. _Paediatric population_ There are very limited safety and immunogenicity data available on the administration of an AS Læs hele dokumentet